Grünenthal GmbH — Biomedical Watch V2

Traitements2programmes

Essais1liés

Publications0liées

SourceDBlocale

Traitements

2

Molécule	Indication / population	Phase	Objectif	Pays	Résultat
GRT6019The purpose of this trial is to assess the safety, tolerability, and PK of 3 doses of GRT6019 in healthy male participants. This Phase I trial will be a multiple dose trial in healthy male participants with administration of GRT6019 in 3 cohorts. For each participant, the trial consists of a Screening Period of up to 28 days, a 4 week Treatment Period (including a 2-week clinic stay and 2 weeks in an outpatient setting), and a 5 week Follow-up Period.	Myopathies	Phase 1	À vérifier	France	À vérifier
GRT6019The purpose of this trial is to assess the safety, tolerability, and PK of 3 doses of GRT6019 in healthy male participants. This Phase I trial will be a multiple dose trial in healthy male participants with administration of GRT6019 in 3 cohorts. For each participant, the trial consists of a Screening Period of up to 28 days, a 4 week Treatment Period (including a 2-week clinic stay and 2 weeks in an outpatient setting), and a 5 week Follow-up Period.	Myopathies	Phase 1	À vérifier	France	À vérifier

Essais cliniques

1

Molécule	Indication / population	Phase	NCT	Titre	Statut
GRT6019	Myopathies	Phase 1	NCT07347548	A Trial to Investigate the Safety and Pharmacokinetics of GRT6019 in Healthy Male Participants	COMPLETED

Publications

0

Molécule	Indication / population	Titre	Journal	Date
Aucune publication.